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The Authors Reply: We thank Drs Komaba and Fukagawa
for their remarks1 and for giving us the opportunity to add to
our review2 some comments on amino-parathyroid hormone
(N-PTH). Determining the exact nature of N-PTH and
understanding its regulation and action(s) is an exciting but
challenging ﬁeld for future research. Although a very
excessive production of N-PTH can be easily evidenced by
the ﬁnding of a third/second-generation PTH ratio 41, we
would like to underline an important technical point. As
several automated third-generation assays will become
available soon, it is likely that many studies will focus on
the third/second-generation PTH ratio. However, this ratio
cannot be calculated from any coupling of PTH assays
(one third-generation and one second-generation assay).
Indeed, both assays must be calibrated similarly (i.e., must
produce the same concentration in a solution of rh1–84 PTH),
and the second-generation assay must measure both 7–84 and
1–84 PTH with 100% cross-reactivity, but must not measure
N-PTH. To our knowledge, this could currently be achieved
only with the Ti-PTH assay (second-generation) and the
CA-PTH assay (third-generation) from Scantibodies Labora-
tories (Santee, CA, USA). Nevertheless, a third/second-
generation PTH ratio 41 is a very rare feature,3 and the
best way to improve our knowledge in N-PTH physiology
would be to develop a simple and direct N-PTH assay.
Indeed, the only published method is complicated and
reserved to highly specialized research laboratories.4 Having
said that, the ﬁnding by Drs Komaba and Fukagawa of the
normalization of a reversed ratio during calcimimetic therapy
is striking and deserves further study.5
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Statins: do we definitely know
whether they are completely
inefficacious in ESRD?
To the Editor: We wish to submit a letter concerning the
paper by Lam et al. in Kidney International.1 Although the
data are certainly of interest, we feel that some note of caution
will put the argument of the authors into a slightly different
perspective.
The paper of Lam et al.1 reports that prescription of statins
in dialysis patients continued unchanged despite the negative
outcome in hemodialyzed patients of one study (4D; Wanner
et al.,2 and in the meantime even in a second one: AURORA3).
The observation is certainly of interest, but we wish to
raise a note of caution regarding the interpretation of the
evidence for the inefﬁcacy of statins.
In the past, it had appeared a priori pathogenetically
plausible that lipid lowering in uremic patients should reduce
cardiac events. That pathophysiological plausibility does
not necessarily translate into evidence-based outcomes of
adequately powered prospective intervention trials has
recently been impressively shown by the TREAT study on
erythropoietin treatment.4
The issue we wish to raise here is the absolute requirement
that studies must be adequately powered before the conclusion
is drawn that a given treatment is ineffective. Indeed both the
4D and the AURORA study were underpowered to provide
biostatistical proof for the efﬁcacy of statins on myocardial
infarction. In both studies the primary outcome was a
composite comprising sudden death and death from other
cardiac causes, including myocardial infraction and stroke.
When planning the studies it was assumed that lipid lowering
by statins would reduce such a combined cardiac and
cerebrovascular end point. Post hoc we noted that statins had
deﬁnitely no signiﬁcant effect with respect to sudden death and
heart failure. However, as we had pointed out elsewhere,5 the
study was presumably underpowered to exclude efﬁcacy for all
types of cardiac death. The post hoc analysis even pointed to a
suggestive beneﬁt for adjudicated coronary end points that
were lower by 19% per 1mmol lowering of low-density
lipoprotein-cholesterol—surprisingly identical with what had
been observed previously in studies on nonrenal cardiac
patients.6
It is also remarkable that both in 4D and the AURORA
study, a trend was seen for separation of the survival curves
approximately 3 years after start of the study—in stark
contrast to the almost immediate effect of statins seen in
nonrenal patients with coronary heart disease. It is possible
that in hemodialyzed patients statins don’t affect inveterate
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pre-existing coronary lesion, yet act on newly formed
lesions—we simply don’t know.
As the power of the study was not sufﬁcient to render the
coronary end point statistically signiﬁcant, it is wise to state
that the currently available data do not allow to draw deﬁnite
conclusions regarding the efﬁcacy of statins on coronary
death in hemodialyzed patients. Absence of evidence is not
necessarily evidence of absence. We have to wait for the
outcome of the SHARP study to know the deﬁnite answer.7
The conclusion that statins are ineffective in dialyzed
patients is certainly not strictly proven and cannot be
answered conclusively today. Admittedly, it is possible that
coronary heart disease in terminal renal disease differs from
coronary heart disease in nonrenal patients and is resistant to
statin treatment as suggested by some previous observa-
tions8,9—but a Socratic attitude demands to admit that
currently we simply don’t know the answer.
We believe that at the current state of our ignorance it is
wise to continue with statins in patients who had been on
statins before dialysis, and, in view of their encouraging side-
effect proﬁle, to administer statins (admittedly without the
deﬁnite evidence) at least in dialysis patients with clinically
proven coronary heart disease.
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The Authors Reply: Ritz and Wanner1 provide insightful
remarks about the need to understand the limitations of
evidence from trials before applying the results in practice. In
our study, statin use in dialysis patients continued to rise
despite the results of the 4D study.2,3 We wish to emphasize
that the purpose of our study was not to applaud or criticize
physicians in their continued use of statins. We agree that
although the evidence from the 4D and AURORA studies
seem to suggest a lack of beneﬁt, the limitations of those trials
make the results less conclusive than they could be.4 Given
the resources needed to conduct randomized trials, it is vital
that they contribute to scientiﬁc knowledge without ambi-
guity. The availability of funds is a major challenge to
conducting trials of common cardiovascular medications.
Industries may be less interested in ﬁnancing these trials, as
dialysis patients represent a small proportion of the overall
market sales. Yet, our need for such evidence remains high, as
renal patients were frequently excluded from trials that
inﬂuenced the use of these medications in the general
population.5 The main purpose of our study was to explore
the translation of knowledge in renal practice. Our discussion
offers several explanations as to why physicians continued to
prescribe statins after the 4D study, which includes
uncertainty about the overall result. As Ritz and Wanner
point out, the SHARP trial will provide more information
about the effectiveness of statins in renal patients.6 We await
these results to guide the care of our patients.
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Very low blood pH is life
threatening
To the Editor: In the review ‘assessing acid–base disorders’,
Adrogue´ et al.1 have discussed the usefulness of three
approaches to assess acid–base disorders with the ﬁnal aim
‘to undertake appropriate intervention’ (p 1239). However,
they have omitted to discuss the importance of blood pH
per se (i.e., the concentration of hydrogen ions (Hþ ) in the
blood).
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